|
Keynote
Speakers: |
 |
Michael
Silber, Ph.D.,
University
of California San Francisco |
|
Daniel
Krewski, Ph.D., MHA
University of Ottawa |
|
|
FEATURED
PRESENTATIONS: |
 |
Carl Alden, Ph.D.
Millennium Pharmaceuticals, Inc. |
 |
Lauren Black, Ph.D.
Charles River Laboratories
|
 |
Eric
Blomme, D.V.M., Ph.D.
Abbott Laboratories
|
 |
Mark
Fielden, Ph.D., DABT
Roche Palo Alto LLC
|
 |
Anna
Georgieva, Ph.D.
Novartis Inc.
|
 |
Ellie
Guardino, M.D., Ph.D.
Stanford University
|
 |
Holly Jordan,
DVM, Ph.D., Dipl. ACVP
GlaxoSmithKline
|
 |
Kathleen Meyer, MPH, Ph.D.
XOMA (US) LLC
|
 |
Jing Min, Ph.D.
Pfi zer Inc. |
 |
Willi
Suter, Ph.D.
Novartis Pharma AG
|
 |
Nancy
Wehner, Ph.D.
Elan Pharmaceuticals |
|
|
SESSIONS INCLUDE:
-
Advances in Toxicity Testing and Prediction
-
Case Studies: Successes and Failures in
Preclinical Development
-
Toxicity Pathways
-
Finding the Relevant Model for Toxicity Testing
of Biopharmaceuticals: Lessons Learned From TeGenero
-
Pathway Approach to Understanding
Off-Target Effects
|
|
Japanese
Korean
English